Skip Links

Desired Superpower

Desired Superpower

Elemental control [to help with climate change]

Favorite Game

Charades

Music

Currently Listening to

Celia Cruz, Sam Cooke, Selena

Favorite Sport

Favorite Sport

Women’s basketball

Quick Facts

If you had a theme song, what would it be?

“Feeling Good” – Nina Simone

Who is your legal hero?

Sonia Sotomayor

If I weren’t a lawyer

I'd be a professional gardener

Curriculum Vitae

NATASHA FERNANDEZ-SILBER is a Partner at Edelson PC, where she is Chair of the firm’s Antitrust practice group. She is based in Ann Arbor, Michigan. 

Natasha’s work focuses on anticompetitive practices in the healthcare and pharmaceutical industries. Among her many active matters, she currently serves as interim Co-Lead Class Counsel in In re Multiplan, No. 24-md-6795 (N.D. Ill.), a price-fixing suit brought on behalf of a proposed class of healthcare providers against major insurers. 

Prior to joining Edelson PC, Natasha was a partner at a litigation boutique specializing in generic drug suppression cases involving “pay-for-delay” deals and other anticompetitive schemes. She has also represented purchasers of e-cigarettes, textbooks, pesticides, and other consumer products. Previously, Natasha clerked for the Honorable Ann Claire Williams on the Seventh Circuit Court of Appeals. She was also an associate at the law firm Wachtell, Lipton, Rosen & Katz, where she focused on restructuring and finance matters. 

  • In re Multiplan, No. 24-md-6795 (N.D. Ill.) – Serves as Interim Co-Lead Class Counsel for proposed class of healthcare providers alleging price-fixing among major insurers and MultiPlan. 
  • Community Care v. GoodRx, No. 24-cv-09490 (C.D. Cal.) – Represents proposed class of independent pharmacies alleging price-fixing among prominent PBMs and GoodRx. 
  • Mass. Laborers’ Health & Welfare Fund v. Boehringer Ingelheim, No. 24-cv-10565 (D. Mass) – Represents proposed class of indirect purchasers alleging drug manufacturer Boehringer Ingelheim has unlawfully monopolized major inhaler markets via wrongful patent listings in FDA’s Orange Book.
  • Reece v. Altria Group, No. 20-02345 (N.D. Cal.) – Steering Committee member representing direct purchasers of Juul products in suit alleging anticompetitive agreement between Juul and Altria.
  • In re Inclusive Access Course Materials Antitrust Litig., No. 20-02946 (S.D.N.Y.) – Appointed Co-Lead Interim Counsel on behalf of college students alleging textbook publishers and retailers conspired to restrict sales of course materials to specific online format to foreclose competition and raise prices.
  • In re Actos Antitrust Litig., No. 15-03278 (S.D.N.Y) – Counsel for direct purchasers in suit alleging Takeda delayed generic competition for diabetes drug by misrepresenting scope of patents listed in Orange Book.
  • In re Ranbaxy Generic Drug Application Antitrust Litig., No. 19-02878 (D. Mass.) – Counsel for direct purchasers in suit alleging Ranbaxy fraudulently obtained tentative ANDA approvals (and first-to-file exclusivities), delaying generic competition in three drug markets.
  • In re Intuniv Antitrust Litig., No. 16-12653 (D. Mass.) – Counsel for direct purchasers in suit alleging reverse payment scheme to monopolize market for ADHD drug.
  • Trial Lawyers of Mass Torts (“TLMT”) Conference, Speaker on “Leadership in Mass Torts and Class Actions” Panel
  • New York
  • Michigan
  • Southern District of New York
  • Seventh Circuit Court of Appeals